Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Experimental study on cisplatinum ototoxicity].

¹First Affiliated Hospital, Bethune University of Medical Sciences, Changchun.

Zhonghua Er Bi Yan Hou Ke Za Zhi

|August 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sequences flanking the pentanucleotide T-antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication.

Journal of virology·1995

Same author

Inactivation and conformation changes of the glycated and non-glycated D-glyceraldehyde-3-phosphate dehydrogenase during guanidine-HCl denaturation.

Biochimica et biophysica acta·1995

Same author

Safe separation of sputum cells from mucoid glycoprotein.

Acta cytologica·1995

Same author

Linkage between sexual orientation and chromosome Xq28 in males but not in females.

Nature genetics·1995

Same author

Dermo-1: a novel twist-related bHLH protein expressed in the developing dermis.

Developmental biology·1995

Same author

Positive regulation of human alpha 1 (I) collagen promoter activity by transcription factor Sp1.

Gene·1995

Same journal

[Culture of neural stem cells from rat olfactory bulb].

Zhonghua er bi yan hou ke za zhi·2005

Same journal

[Research of fibronectin, p53 and Ezrin protein with occurrence, progress and prognosis in the primary laryngeal carcinoma by the tissuechip technology].

Zhonghua er bi yan hou ke za zhi·2005

Same journal

[Effects of basic fibroblast growth factor on protein kinase B activity and c-fos expression in CNE- I nasopharyngeal carcinoma cell line].

Zhonghua er bi yan hou ke za zhi·2005

Same journal

[Nasal alar reconstruction with a vascularized free auricular composite flap].

Zhonghua er bi yan hou ke za zhi·2005

Same journal

[Effect of intranasal glucosteroid on the gene expression of interleukin-5 in nasal polyps].

Zhonghua er bi yan hou ke za zhi·2005

Same journal

[Roles of epidermal growth factor and its receptor on the chronic tympanic membrane perforations].

Zhonghua er bi yan hou ke za zhi·2005

See all related articles

Cisplatinum chemotherapy can cause progressive hearing loss (ototoxicity) by damaging inner ear hair cells and spiral ganglion neurons. This effect is dose-dependent and may stem from inhibited protein synthesis.

Area of Science:

Oto-neuroscience
Pharmacology
Cell Biology

Context:

Cisplatinum is a widely used chemotherapy drug for various cancers.
Ototoxicity is a significant and dose-limiting side effect of cisplatinum treatment.
Understanding the cellular mechanisms of cisplatinum ototoxicity is crucial for mitigating its impact.

Purpose:

To investigate the ototoxic effects of cisplatinum on the inner ear.
To identify the cellular targets of cisplatinum-induced ototoxicity.
To explore potential mechanisms underlying cisplatinum ototoxicity.

Summary:

Cisplatinum exhibits significant ototoxic effects, impacting both cochlear hair cells and spiral ganglion neurons.
Experimental evidence demonstrates that cisplatinum damages these critical auditory structures.

Related Experiment Videos

Inhibition of protein synthesis and cellular metabolism are proposed as primary mechanisms responsible for cisplatinum's ototoxicity.

The ototoxicity induced by cisplatinum is progressive and exacerbated by higher doses.

Impact:

This research provides insights into the cellular basis of cisplatinum-induced hearing loss.
Findings may inform strategies for developing neuroprotective agents or treatment protocols to reduce ototoxicity.
Highlights the importance of monitoring auditory function in patients receiving cisplatinum therapy.